Search Results - "Cirauqui, B. Cirauqui"

Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population by Viros Porcuna, D., Pollan Guisasola, C., Viña Soria, C., Cirauqui Cirauqui, B., Pardo Muñoz, L., Collurá, F., Mesia Nin, R.

“…Purpose Transoral robotic surgery (TORS) is one of the main treatment options for non-locally advanced primary oropharyngeal cancer in the United States…”
Get full text

SEOM clinical guidelines for the treatment of head and neck cancer (2017) by Iglesias Docampo, L. C., Arrazubi Arrula, V., Baste Rotllan, N., Carral Maseda, A., Cirauqui Cirauqui, B., Escobar, Y., Lambea Sorrosal, J. J., Pastor Borgoñón, M., Rueda, A., Cruz Hernández, J. J.

“…Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain…”
Get full text

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study by Martínez-Trufero, J., Lozano Borbalas, A., Pajares Bernad, I., Taberna Sanz, M., Ortega Izquierdo, E., Cirauqui Cirauqui, B., Rubió-Casadevall, J., Plana Serrahima, M., Ponce Ortega, J.M., Planas Toledano, I., Caballero, J., Marruecos Querol, J., Iglesias Docampo, L., Lambea Sorrosal, J., Adansa, J. C., Mesía Nin, R.

“…Background Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as induction treatment (IT) followed by concurrent bioradiotherapy (Bio–RT) with Pb…”
Get full text

268P Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions by Pla, H., Recalde Penabad, S., Vinas Villaro, G., Margeli Vila, M., Obadia Gil, V.L., Cirauqui Cirauqui, B., Del Barco Berron, S., Gil, M.J., Quiroga Garcia, V., Teruel-Garcia, I., Pernas Simon, S., Stradella, A., Esteve Gomez, A.M., Felip, E.

Get full text

88P Genetic platforms in hormone receptor (HR)+ early breast cancer (eBC): Could logistic regression models be used instead? by Lopez Paradis, A., Pous, A., Notario Rincon, L., Sebastià, G. Cerdà, Sant Albors, M., Bergamino, M.A., Ferrando Diez, A., Teruel-Garcia, I., Romeo Marin, M., Quiroga Garcia, V., Cirauqui Cirauqui, B., Margeli Vila, M., Felip Falgas, E.

Get full text

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study by Alba, E., Chacon, J. I., Lluch, A., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Segui, M. A., Ribelles, N., Alvarez, R., Sanchez-Muñoz, A., Sanchez, R., Garcia-Asenjo, J. A. Lopez, Rodriguez-Martin, C., Escudero, M. J., Albanell, J.

“…Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II…”
Get full text

33P Epigenetic biomarkers ID1, HOXB2 and ATOH8 could predict response to chemotherapy and prognosis in early breast cancer by Quiroga Garcia, V., Moran, S., Queralt, C., Cabrero, S., Bernat, A., Ferrando Diez, A., Perez, L., Cirauqui Cirauqui, B., Felip, E., Teruel-Garcia, I., Romeo Marin, M., Pous, A., Castellà, E., Martinez-Cardús, A., Margeli, M.

Get full text

664P A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era by Bossi, P., Alberti, A., Zamparini, M., Orlandi, E., Grisanti, S., Trama, A., Resteghini, C., Mesia Nin, R., Mohamad, I., Ozyar, E., Buglione, M., Airoldi, M., Vecchio, S., Livi, L., Cirauqui Cirauqui, B., El-Sherify, M., Ursino, S., Argiris, A., Linares Galiana, I., Licitra, L.F.

Get full text

678P Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) by Cirauqui Cirauqui, B., Martinez Trufero, J., Plana Serrahima, M., García Castaño, A., Rubió-Casadevall, J., Carral Maseda, A., Iglesias Docampo, L., Pérez Segura, P., Ceballos Lenza, I., Gutierrez Calderon, V., Fuster Salva, J., Pena Álvarez, C., Arrazubi Arrula, V., del Barco Morillo, E., Chaves Conde, M., Martínez Galán, J., Durán Sánchez, M., Quiroga, V., Ortega, E., Mesia Nin, R.

Get full text

965P Role of STAT3 (signal transducer and activator of transcription 3) activation and its regulation by PTPRT (protein receptor tyrosine phosphatase type T) and response to paclitaxel and cetuximab in patients (P) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) by Cirauqui Cirauqui, B., Bernat Peguera, A., Quer Pi-Sunyer, A., Ramírez Serrano, J.L., Domenech Viñolas, M., Teruel García, I., Quiroga García, V., Margeli Vila, M., Chaib, I., Capdevila Riera, L., Ferrando Diez, A., Plaja Salarich, A., Angelats Company, L., España Fernandez, S., Berenguer Peinado, G., Lezcano Rubio, C., Pollan Guisasola, C., Martinez Cardús, A., Rosell Costa, R., Mesia Nin, R.

Get full text

940P Analysis of a cohort of elderly patients (p) with head and neck cancer (HNC) managed within a multidisciplinary head and neck cancer unit (HNCU) by Ferrando Diez, A., Viros Porcuna, D., Teruel García, I., Planas Toledano, I., Garcia Linares, J., Cuadras Collsamata, P., Quer Pi-Sunyer, A., Viña Soria, C., Carrasco Lopez, C., Traboulsi Garet, T., Massuet Vilamajo, A., Palau Viarnes, M.D.M., Sendros Madroño, M.J., Hernandez Vergara, P., Vila Poyatos, J., Bordonaba Leiva, S., Puyalto de Pablo, P., Perez Gomez, J.A., Cirauqui Cirauqui, B., Pollan Guisasola, C.

Get full text

Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA by Martinez Trufero, J., Mesia Nin, R., Ortega Izquierdo, M.E., Lozano, A., Cirauqui Cirauqui, B., Rubió Casadevall, J., Taberna Sanz, M., Pastor Borgoñon, M., Lambea Sorrosal, J., Iglesias, L., Vázquez, S., del Barco Morillo, E., Perez Segura, P., Lopez Pousa, A., Ponce, J.M., Cruz-Hernández, J.J.

Get full text

1113PDSurvival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: A large multicentric database analysis by Bossi, P, Grisanti, S, Mohamad, I, Linares Galiana, I, Ozyar, E, Franco, P, Vecchio, S, Livi, L, Cirauqui Cirauqui, B, El-Sherify, M, Ursino, S, Argiris, A, Pan, J, Wittekindt, C, D’angelo, E, Buglione, M, Airoldi, M, Mesia Nin, R, Licitra, L F, Orlandi, E

“…Abstract Background Nasopharyngeal carcinoma (NPC) is a rare cancer in many areas including Europe and Middle East/Mediterranean. Data regarding natural…”
Get full text

1159P - The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients by Herrera Gomez, R.G., Mezquita, L., Auclin, E., Heraudet, L., Plana, M., Salas, S., Cristina, V., Garcia Castano, A., Arrazubi, V., Grau, J.J., Saleh, K., Cirauqui Cirauqui, B., Mesia Nin, R., Even, C., Taberna, M., Daste, A., Peters, S., Besse, B., Baste-Rotllan, N.

“…LIPI, based on derived NLR (neutrophils/(leucocytes-neutrophils)) and lactate dehydrogenase (LDH) level, has been correlated to ICI outcomes in advanced non…”
Get full text

Survival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: A large multicentric database analysis by Bossi, P., Grisanti, S., Mohamad, I., Linares Galiana, I., Ozyar, E., Franco, P., Vecchio, S., Livi, L., Cirauqui Cirauqui, B., El-Sherify, M., Ursino, S., Argiris, A., Pan, J., Wittekindt, C., D’angelo, E., Buglione, M., Airoldi, M., Mesia Nin, R., Licitra, L.F., Orlandi, E.

Get full text

1128PFinal results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA by Martinez Trufero, J, Mesia Nin, R, Ortega Izquierdo, M E, Lozano, A, Cirauqui Cirauqui, B, Rubió Casadevall, J, Taberna Sanz, M, Pastor Borgoñon, M, Lambea Sorrosal, J, Iglesias, L, Vázquez, S, del Barco Morillo, E, Perez Segura, P, Lopez Pousa, A, Ponce, J M, Cruz-Hernández, J J

“…Abstract Background Patients (pts) not candidates to platinum-based therapies have limited therapeutic options. The addition of P to PTX followed by RT + P may…”
Get full text

1128P - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA by Martinez Trufero, J., Mesia Nin, R., Ortega Izquierdo, M.E., Lozano, A., Cirauqui Cirauqui, B., Rubió Casadevall, J., Taberna Sanz, M., Pastor Borgoñon, M., Lambea Sorrosal, J., Iglesias, L., Vázquez, S., del Barco Morillo, E., Perez Segura, P., Lopez Pousa, A., Ponce, J.M., Cruz-Hernández, J.J.

“…Patients (pts) not candidates to platinum-based therapies have limited therapeutic options. The addition of P to PTX followed by RT + P may be an alternative…”
Get full text

1113PD - Survival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: A large multicentric database analysis by Bossi, P., Grisanti, S., Mohamad, I., Linares Galiana, I., Ozyar, E., Franco, P., Vecchio, S., Livi, L., Cirauqui Cirauqui, B., El-Sherify, M., Ursino, S., Argiris, A., Pan, J., Wittekindt, C., D’angelo, E., Buglione, M., Airoldi, M., Mesia Nin, R., Licitra, L.F., Orlandi, E.

“…Nasopharyngeal carcinoma (NPC) is a rare cancer in many areas including Europe and Middle East/Mediterranean. Data regarding natural history, prognostic…”
Get full text

1159PThe head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients by Herrera Gomez, R G, Mezquita, L, Auclin, E, Heraudet, L, Plana, M, Salas, S, Cristina, V, Garcia Castano, A, Arrazubi, V, Grau, J J, Saleh, K, Cirauqui Cirauqui, B, Mesia Nin, R, Even, C, Taberna, M, Daste, A, Peters, S, Besse, B, Baste-Rotllan, N

“…Abstract Background LIPI, based on derived NLR (neutrophils/(leucocytes-neutrophils)) and lactate dehydrogenase (LDH) level, has been correlated to ICI…”
Get full text

The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients by Herrera Gomez, R.G., Mezquita, L., Auclin, E., Heraudet, L., Plana, M., Salas, S., Cristina, V., Garcia Castano, A., Arrazubi, V., Grau, J.J., Saleh, K., Cirauqui Cirauqui, B., Mesia Nin, R., Even, C., Taberna, M., Daste, A., Peters, S., Besse, B., Baste-Rotllan, N.

Get full text